Prosecution Insights
Last updated: April 19, 2026

Erasca Inc.

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18572399 ERK1/2 AND KRAS G12C INHIBITORS COMBINATION THERAPY ANDERSON, REBECCA L 1626 Non-Final OA Dec 20, 2023
18572412 SHP2 AND CDK4/6 INHIBITORS COMBINATION THERAPIES FOR THE TREATMENT OF CANCER KUCKLA, ANNA GRACE 1626 Non-Final OA Dec 20, 2023
18256089 COMBINATION THERAPIES FOR THE TREATMENT OF CANCER DAHLIN, HEATHER RAQUEL 1629 Non-Final OA Jun 06, 2023
18256091 COMBINATION THERAPIES FOR THE TREATMENT OF CANCER BURKETT, DANIEL JOHN 1624 Non-Final OA Jun 06, 2023
18027313 COMPOSITIONS AND METHODS FOR TREATING CANCER BURKETT, DANIEL JOHN 1624 Final Rejection Mar 20, 2023

Managing Erasca Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month